T1-High-Risk-Harnblasenkarzinom

T1 high risk bladder cancer is associated with high recurrence and progression rates. Furthermore, lymph node metastasis will be observed in approximately 10% of the patients. Therapeutic options include early radical cystectomy or bladder preservation and are subject to controversial discussion. Concomitant carcinoma in situ and persistent T1 high risk disease during repeated transurethral resection (TUR) are associated with an exceedingly high progression risk. In these cases as well as for multifocal and/or extensive T1 tumors early cystectomy is recommended. For unifocal T1 tumors which are no longer present during repeated TUR and without concomitant carcinoma in situ, a bladder sparing approach appears to be a reasonable option and includes adjuvant intravesical BCG therapy including maintenance cycles for at least 1 year.     

Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

Breast Cancer Research and Treatment - National comprehensive cancer network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple-negative breast cancer (TNBC) if the...     

Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification

The objectives of this study were to investigate the long-term results of T1a, T1b and T1c Japanese invasive breast cancer patients defined by the UICC classification. The subjects were T1a (38), T1b (256) and T1c (1405) Japanese invasive breast cancer patients. Ten- and 20-year disease-free survival (DFS) and overall survival (OS) rates were analyzed by the UICC T1 subgroups (T1a, T1b, T1c). At 10 years, the respective DFS and OS rates of T1a, T1b and T1c patients were 91.9 and 91.9%, 86.1 and 86.8% and 82.4 and 83.9%, respectively. At 20 years, the respective DFS and OS rates of T1a, T1b and T1c patients were 70.7 and 70.7%, 76.7 and 76.7% and 69.1 and 70.1%. The differences of DFS and OS between T1a and T1c patients were not statistically significant. The DFS of patients with T1c breast carcinoma showed a statistically significant difference from that of T1b patients (p = 0.03). The validation of the T1 subgroup classification in Japanese breast cancer patients was confirmed, particularly for the T1c subgroup.     

三阴性对小肿块乳腺癌患者预后的影响

  目的  分析小肿块（直径≤1 cm）乳腺癌患者的临床及病理学特征,了解其生存状态,探讨三阴性对其预后的影响。  方法  收集本院收治的312例直径≤1 cm乳腺癌患者的临床病理学资料,比较三阴性乳腺癌及非三阴性乳腺癌的临床病理学特征、复发转移及生存情况。  结果  312例直径≤1 cm乳腺癌患者纳入研究,三阴组及非三阴组5年DFS分别为81.4%及90.5%（P= 0.038）,5年BCSS分别为84.7%及93.7%（P=0.047）。以淋巴结状态分组比较,淋巴结阴性患者中,三阴组及非三阴组5年DFS分别为82.8%及94.1%（P=0.033）,5年BCSS分别为85.0%及96.1%（P=0.019）。Cox比例风险模型多因素分析显示,淋巴结阳性患者复发转移风险增高（HR=3.721,95%CI:1.743~7.941,P=0.001）,死亡风险亦增高（HR=3.560,95%CI:1.521~8.330,P=0.003）,三阴性患者复发转移风险增高（HR=2.208,95%CI:1.028~4.742,P=0.042）。  结论  淋巴结阳性及三阴性是影响直径≤1 cm乳腺癌患者DFS的独立危险因素,淋巴结阳性是影响BCSS的唯一独立危险因素。淋巴结阴性三阴性乳腺癌组较非三阴组预后差。      

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40-9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04-4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56-13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44-7.18) and overall survival (HR 2.87; 95%CI: 1.05-7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease.     

Results of implantation for T1 and T2 bladder tumours

In the period from January 1972 through December 1983 a total of 123 patients was treated for a bladder malignancy by preoperative external irradiation followed by interstitial therapy. Criteria for selection of patients are solitary lesion, tumour smaller than 5 cm in diameter, state T1 and T2. The majority of patients was in state T2 (89 patients). Persisting local control was achieved in 29 out of 34 T1 cases and in 69 out of 85 T2 cases. The actuarial 10 years survival was 72% for T1 and 34% for T2, with a total disease-free percentage at 10 years of 77% for T1 and 56% for T2. Although in many patients delayed wound healing was noticed, no serious late reactions were seen in skin, bladder or intestine. The causes of death are distant metastases in 13 patients and intercurrent diseases in another 21 patients.     

Proton spinlocking and T1 rho-weighted MR imaging at 1.5 T

During spinlocking, the magnetization is aligned along an oscillating field (RF) and relaxes with time constant T1 rho, the spin-lattice relaxation time in the rotating frame. Using a clinical whole-body MR scanner, methods of spinlocking preparation and signal acquisition were combined to evaluate the potential of T1 rho-weighted MR imaging (T1 rho w-MRI) at B0 = 1.5 T. Examinations of the brain of healthy volunteers yielded images with pronounced contrast and T1 rho-variation of the tissue. However, the contrast resembled that of T2-weighted MRI, which is explained by the restricted spinlocking-field strength (BSL < or = 6 microT) on the tomograph. The result (mono-exponential fit) of serial T1 rho w-MRI data from examinations of 8 volunteers was on average 105 +/- 4 ms in the gray matter and 86 +/- 4 ms in the white matter (for BSL = 3 microT). The values are comparable to T2 of both tissues. MRT with spinlocking is less susceptible to local magnetic field inhomogeneities than conventional MRI.     

Management of Early (T1 or T2) Rectal Cancer

Early stage rectal cancers (T1/T2) are being found more commonly due to increasing compliance with population screening guidelines. Patient selection is the most important element in advising local excision versus standard transabdominal resection with total mesorectal excision (TME). Determining the best strategy for an individual patient relies on accurate histologic assessment (a surrogate of biologic behavior), accurate clinical staging (endorectal ultrasound or MRI), and accurate assessment of patient procedural risk. It is important to review the histology for high-risk features associated with occult lymph node metastasis as this portends a higher local recurrence rate. Since the local recurrence rate following local excision for T2 rectal cancer is high, it has been our practice to offer these patients proctectomy with TME unless the patient has a poor performance status, is unwilling to proceed, or is part of a clinical trial. We limit transanal resection to well-selected patients with T1 lesions without high-risk histologic features (lymphovascular invasion, poor grade, or deep submucosal invasion). Factors such as patient procedural preference and comorbidities may influence this decision but it is on a case by case basis. Local excision can be accomplished with conventional transanal procedures; however, newer techniques such as transanal endoscopic microsurgery (TEM) and transanal minimally invasive surgery (TAMIS) may have less specimen fragmentation and improved R0 resection rates. Neoadjuvant chemoradiation may add further benefit for maximizing local control but is associated with local wound problems including bleeding and infection. Adherence to a strict surveillance program after local excision allows clinicians to salvage recurrence as early as possible. In a multidisciplinary fashion, the surgeon, pathologist, gastroenterologist, and patient need to make informed decisions about risk and benefit when determining the best individualized care for the patient.     

Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features

Glucose uptake is mediated by glucose transporter (Glut) proteins, which exhibit altered expression in a variety of malignant neoplasms. Glut1 expression is thought to be a potential marker for malignant transformation. The aim of the present study was to investigate the expression of Glut1 protein in colorectal adenomas, T1 and T2 stage carcinomas. Immunohistochemical detection of Glut1 protein was examined in 141 formalin-fixed and paraffin-embedded colorectal tumour specimens (57 adenomas, 84 carcinomas). The degree of Glut1 immunostaining of a specimen was graded according to the proportion of Glut1-positive cells in it; absent (positive cells are 0%), weakly positive (less than 10%), moderately positive (10-50%), and strongly positive (more than 50%). Glut1 expression was present in 18% of the adenomas with low-grade dysplasia, and in 63% of the adenomas with high-grade dysplasia. The positivity in such lesions was usually weak, but was moderate in 8% of the adenomas with high grade dysplasia. For the carcinomas, there were significant correlations between Glut1-positivity and depth of invasion (T1 45% versus T2 74%, P<0.01), histological differentiation (well 49% versus moderately to poorly 74%, P< 0.05) and morphological type (polypoid 42% versus depressed 73%, P< 0.05), if the cut-off value was set at 10% of cells. In conclusion, we clarified the relationship between Glut1 expression and clinicopathological features in T1 and T2 stage colorectal carcinomas, and our results suggested a high malignant potential of the depressed-type carcinoma.     

Management of T1a breast cancer

Identification of early-stage breast cancers has increased over the past 2 decades primarily because of mammographic screening. The general guidelines to management of breast cancer may not apply to the smallest of these tumors, as their metastatic potential may be smaller than larger tumors. Tumors < 5 mm (T1a) carry an excellent prognosis, despite a variety of treatment approaches. However, some patients' cancer returns. There appear to be some histologic features that can predict a higher risk of axillary metastases, and therefore, a higher risk of distant metastases. Controversy exists over the extent of treatment, as to whether less than conventional treatment, such as mastectomy, axillary evaluation, and breast-conserving surgery and radiation, can be done. T1a lesions associated with extensive ductal carcinoma in situ and T1a lesions in young patients should be treated with caution if less than conventional breast treatment is to be considered. In older patients with good histologic features, axillary assessment may not be necessary. Very wide excision alone may be appropriate for some patients, but partial breast irradiation is under study and may provide a reasonable compromise. Systemic therapy for node-negative patients is not recommended. Recurrences within the breast occur later in early-stage breast cancers than with extensive-stage breast cancers, requiring annual imaging and evaluation for many years.     

BREAST CONSERVING THERAPY IN STAGE T1 ＆ T2 BREAST CANCER PATIENTS

Objective: To investigate the effect of breast-conservation therapy in early stage breast cancer. Methods: A total of 234 early stage breast carcinoma patients received breast conserving treatment in our hospital. After the operation, they underwent adjuvant chemotherapy and radiotherapy. All of these patients desired to preserve their breasts. Results: After median follow-up of 29.46 months (range from 3 to 100 months), 3 cases had local relapse and 8 cases had distant metastasis. The overall survival rate of 5 year was 96.7%, and the disease free survival rate of 5 year was 87.85%. Conclusion: For early stage breast carcinoma patients, classic quadrantectomy, axillary dissection and post-operative adjuvant chemotherapy and radiotherapy lead to excellent local control and good survival.     

T1micN0M0、T1aN0M0和T1bN0M0乳腺癌376例临床特征和预后分析

目的:分析T1micN0M0、T1aN0M0和T1bN0M0乳腺癌患者的临床病理学特征,了解其生存状态,探讨与预后相关的独立影响因素。方法:收集2002年1月—2005年12月4487例可手术的乳腺癌患者的临床病理学资料,回顾性分析其中376例T1micN0M0、T1aN0M0和T1bN0M0患者的临床病理学特征、复发和转移以及生存情况。结果:376例患者中,66例(17.6%)为T1mic(pT≤0.1cm),122例(32.4%)为T1a(0.1cm相似文献   

T1和T2期直肠癌淋巴结转移特点及预后

目的 探讨T1和T2期直肠癌淋巴结的转移特点及预后。方法 回顾性分析241例T1和T2期直肠癌的淋巴结转移特点,用X^2检验分析其相关因素,并对预后进行单因素及多因素分析。结果T1和T2期直肠癌行Mile＇s术132例,保肛术109例,淋巴结转移率为22．0％（53／241）,X^2。检验显示,肿瘤分化程度与淋巴结转移有关。5年生存率为91．5％。单因素分析显示,肿瘤组织学类型、浸润深度、分化程度、淋巴结转移、放疗与预后相关。多因素分析显示,肿瘤浸润深度为T1和T2期直肠癌患者预后的主要影响因素。结论 T1和T2期直肠癌均可发生淋巴结转移,肿瘤分化与淋巴结转移相关,根治性切除术预后较好,应作为首选的治疗方法。     

Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy

BACKGROUND:

The authors evaluated the clinical characteristics, natural history, and outcomes of patients who had ≤1 cm, lymph node‐negative, triple‐negative breast cancer (TNBC).

METHODS:

After excluding patients who had received neoadjuvant therapy, 1022 patients with TNBC who underwent definitive breast surgery during 1999 to 2006 were identified from an institutional database. In total, 194 who had lymph node‐negative tumors that measured ≤1 cm comprised the study population. Clinical data were abstracted, and survival outcomes were analyzed.

RESULTS:

The median follow‐up was 73 months (range, 5‐143 months). The median age at diagnosis was 55.5 years (range, 27‐84 years). Tumor (T) classification was microscopic (T1mic) in 16 patients (8.2%), T1a in 49 patients (25.3%), and T1b in 129 patients (66.5%). Most tumors were poorly differentiated (n = 142; 73%), lacked lymphovascular invasion (n = 170; 87.6%), and were detected by screening (n = 134; 69%). In total, 129 patients (66.5%) underwent breast‐conserving surgery, and 65 patients (33.5%) underwent mastectomy. One hundred thirteen patients (58%) received adjuvant chemotherapy, and 123 patients (63%) received whole‐breast radiation. The patients who received chemotherapy had more adverse clinical and disease features (younger age, T1b tumor, poor tumor grade; all P < .05). Results from testing for the breast cancer (BRCA) susceptibility gene were available for 49 women: 19 women had BRCA1 mutations, 7 women had BRCA2 mutations, and 23 women had no mutations. For the entire group, the 5‐year local recurrence‐free survival rate was 95%, and the 5‐year distant metastasis‐free survival rate was 95%. There was no difference between patients with T1mic/T1a tumors and patients with T1b tumors in the distant recurrence rate (94.5% vs 95.5%, respectively; P = .81) or in the receipt of chemotherapy (95.9% vs 94.5%, respectively; P = .63).

CONCLUSIONS:

Excellent 5‐year locoregional and distant control rates were achievable in patients with TNBC who had tumors ≤1.0 cm, 58% of whom received chemotherapy. These results identified a group of patients with TNBC who had favorable outcomes after early detection and multimodality treatment. Cancer 2012. © 2012 American Cancer Society.     

Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue

Between 1970 and 1986, 166 patients with T1 or T2 epidermoid carcinomas of the mobile tongue were treated by iridium 192 implantation (70 T1N0, 83 T2N0, 13 T1-2 N1-3). Five-year actuarial survival was 52% for T1N0, 44% for T2aN0, and 8% for or T1-2 N1-3. Cause specific survivals were 90%, 71%, and 46%, respectively. Local control was 87% for both T1N0 and T2N0, and 69% for T1-2 N1-3. Seven of 23 failures were salvaged by surgery, increasing local control to 96% for T1 and 90% for T2. Thirty-six patients developed a minor or moderate necrosis (16% T1, 28% T2). Half of these involved bone but only five required surgical intervention. Both local control (LC) and necrosis (nec) increased with increasing dose but improvement beyond 65 Gy is minimal (less than or equal to 60 Gy: LC = 78% nec = 13%; 65 Gy: LC = 90% nec = 29%; greater than or equal to 70 Gy: LC = 94% nec = 23%). For N0 patients, neck management consisted of surveillance (n = 78), elective neck dissection followed with external irradiation for pathologically positive nodes (n = 72), or irradiation (n = 3). Clinically positive nodes (13 patients) were managed by either neck dissection followed by external irradiation if pathologically positive (n = 10) or irradiation alone (n = 3). Regional control was 79% for N0 patients, improving to 88% after surgical salvage, and was 9/13 for N1-3 patients. We recommend that T1 and T2 carcinomas of the mobile tongue be treated by iridium 192 implantation to deliver 65 Gy. Mandibular necrosis should be reduced by using an intra-oral lead-lined dental mold.